FilingReader Intelligence
China Resources Pharmaceutical subsidiaries report interim results
August 22, 2025 at 09:39 AM UTC•By FilingReader AI
China Resources Pharmaceutical Group announced interim results for two subsidiaries for the six months ended June 30, 2025.
CR Boya Bio-pharmaceutical reported 1.01 billion yuan revenue and 225 million yuan net profit, while CR Double-Crane generated 5.74 billion yuan revenue and 975 million yuan net profit.
Both subsidiaries proposed cash dividends.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
HKEX:3320•Hong Kong Exchange
News Alerts
Get instant email alerts when China Resources Pharmaceutical Group publishes news
Free account required • Unsubscribe anytime